MedTrace Logo

Treatment Patterns in Metastatic Prostate Cancer

NCT02729103 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 565

Last updated 2018-01-25

No results posted yet for this study

Summary

This study will evaluate treatment patterns, mortality, healthcare resource utilization, and costs in patients with prostate cancer with bone metastases (primary objectives). Additionally, this study will evaluate opioid/analgesic use among lines of therapy in this patient population (secondary objective). The study is descriptive in nature and is meant to provide a greater understanding of the patterns of therapy observed in real-world clinical practice (in the absence of clear guideline recommendations with regards to treatment sequencing), to contribute to a greater understanding of the major cost drivers (thus better-informing payers), and to examine real-world mortality in such patients.

Conditions

  • Prostatic Neoplasm

Interventions

DRUG

Xofigo (Radium 223 dichloride,BAY88-8223)

Retrospective claims analysis. Descriptive analyses of treatment patterns.

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
45 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2017-01-19
Completion
2017-01-19

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02729103 on ClinicalTrials.gov